Search results for "Anilide"

showing 10 items of 40 documents

Apoptosis induced in HepG2 cells by the synthetic cannabinoid WIN: involvement of the transcription factor PPARgamma.

2008

It has recently been shown that cannabinoids induce growth inhibition and apoptosis in different tumour cell lines. In the current study, the effects of WIN 55,212-2 (WIN), a synthetic and potent cannabinoid receptor agonist, are investigated in hepatoma HepG2 cells and a possible signal transduction pathway is proposed. In these cells, WIN induces a clear apoptotic effect which was accompanied by up-regulation of the death-signalling factors Bax, Bcl-X(S), t-Bid and down-regulation of the survival factors survivin, phospho-AKT, Hsp72 and Bcl-2. Moreover, WIN-induced apoptosis is associated with JNK/p38 MAPK pathway activation and mitochondrial depolarisation demonstrated by a cytofluorimet…

Cannabinoid receptorCarcinoma HepatocellularCell SurvivalPyridinesmedicine.medical_treatmentp38 mitogen-activated protein kinasesMorpholinesApoptosisBiologyNaphthalenesBiochemistryReceptor Cannabinoid CB2Membrane Microdomainscannabinoids PPARgamma factor apoptosis cancer cellsSettore BIO/10 - BiochimicaCell Line TumorSurvivinmedicineHumansAnilidesViability assayCannabinoidsLiver NeoplasmsGeneral MedicineCell biologyBenzoxazinesPPAR gammaApoptosisCancer cellBenzamidesCannabinoidSignal transductionApoptosis Regulatory ProteinsProtein KinasesSignal TransductionBiochimie
researchProduct

Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial.

2021

Summary Background Before February, 2021, there was no standard treatment regimen for locally advanced basal cell carcinoma after first-line hedgehog inhibitor (HHI) therapy. Cemiplimab, a PD-1 antibody, is approved for treatment of advanced cutaneous squamous cell carcinoma and has shown clinical activity as monotherapy in first-line non-small-cell lung cancer. Here, we present the primary analysis data of cemiplimab in patients with locally advanced basal cell carcinoma after HHI therapy. Methods We did an open-label, multicentre, single-arm, phase 2 trial across 38 outpatient clinics, primarily at academic medical centres, in Canada, Europe, and the USA. Eligible patients (aged ≥18 years…

AdultMalemedicine.medical_specialtySkin NeoplasmsPyridinesProgrammed Cell Death 1 ReceptorVismodegibAntibodies Monoclonal Humanized030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaClinical endpointOutpatient clinicHumansBasal cell carcinomaAnilidesHedgehog ProteinsLung cancerImmune Checkpoint InhibitorsAgedbusiness.industryStandard treatmentMiddle Agedmedicine.diseaseRegimenOncologyCarcinoma Basal CellDrug Resistance Neoplasm030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drugThe Lancet. Oncology
researchProduct

ortho-Substituent effects inN-arylacetamides. NMR and molecular mechanics investigation

1995

1H, 13C, 15N and 17O NMR spectra of N-phenylacetamide (acetanilide) and 21 ortho-substituted acetanilides were measured and assigned. The observed NMR parameters are related to the Hammett substituent parameters and conformational characteristics of the acetamido moiety estimated by molecular mechanics calculations. Significant relationships were found for the 13C NMR chemical shifts of C-5 (para to substituent) and the direct spin–spin coupling constant, 1J(C, H), of C-3 (ortho to substituent) with Hammett substituent parameters. For 15N NMR chemical shifts of the amido nitrogen, no general correlation with the Hammett substituent parameters was found. The interactions between functionalit…

Steric effectsChemistryStereochemistryChemical shiftOrganic ChemistrySubstituentCarbon-13 NMRRing (chemistry)Resonance (chemistry)Medicinal chemistrychemistry.chemical_compoundMoietyPhysical and Theoretical ChemistryAcetanilideJournal of Physical Organic Chemistry
researchProduct

Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

2018

Purpose: To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in the sub-group of GT1 patients older than 65 years. Methods: We collected data extracted from the ABACUS compassionate-use nationwide Italian programme, in patients with cirrhosis due to hepatitis C virus (HCV) Genotype-1 (GT1) or 4 and at high risk of decompensation. GT1-HCV-infected patients received once-daily ombitasvir/paritaprevir, with the pharmacokinetic enhancer ritonavir (25/150/100 mg) and twice-daily dasabuvir (250 mg) plus Ribavirin (RBV) (OBV/PTV/r + DSV + RBV) for 12 (GT1b) or 24 (GT1a) weeks. Endpoints were to evaluate safety and efficacy, the latter def…

CyclopropanesLiver CirrhosisMaleCirrhosis;Dasabuvir;Elderly;Ombitasvir;ParitaprevirCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged; 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy; Combination; GenotypeParitaprevirCirrhosis Dasabuvir Elderly Ombitasvir Paritaprevir Microbiology (medical) Infectious DiseasesCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; Genotype; Microbiology (medical); Infectious DiseasesHepacivirusGastroenterologychemistry.chemical_compound0302 clinical medicineElderly2-Naphthylamine80 and overMedicineAnilides030212 general & internal medicineChronicAged 80 and overSulfonamidesDasabuvirValineGeneral MedicineHepatitis CHepatitis CTreatment OutcomeInfectious DiseasesCirrhosisCombination030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleDasabuvirMacrocyclic CompoundCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Microbiology (medical); Infectious Diseasesmedicine.drugHumanMicrobiology (medical)medicine.medical_specialtyMacrocyclic CompoundsProlineGenotypeLactams MacrocyclicSettore MED/12 - GASTROENTEROLOGIALiver CirrhosiSulfonamideAntiviral Agents03 medical and health sciencesDrug TherapyInternal medicineRibavirinHumansDecompensationUracilAgedHepatitisAntiviral AgentCirrhosiHepaciviruRitonavirbusiness.industryRibavirinSettore MED/09 - MEDICINA INTERNAAnilideBiomarkerHepatitis C Chronicmedicine.diseaseCirrhosis; Dasabuvir; Elderly; Ombitasvir; Paritaprevir; Aged; Aged 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Female; Hepacivirus; Hepatitis C Chronic; Humans; Liver Cirrhosis; Macrocyclic Compounds; Male; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Drug Therapy Combination; GenotypeOmbitasvirOmbitasvirchemistryParitaprevirCarbamateRitonavirCarbamatesbusinessBiomarkers
researchProduct

Hsp60 Inhibitors and Modulators

2019

In this chapter, we focus on the 60 KDa Heat Shock Protein (Hsp60) and discuss some of its biological, molecular and pathological features. The structural and mechanistic aspect of the Hsp60 folding cycle will be also presented. We further illustrate how Hsp60 may be involved in many diseases and therefore considered as an effective therapeutic or theranostic target. Finally, the state-of-the-art on the development of Hsp60 and bacterial GroEL inhibitors and modulators of their expression will be illustrated. This is discussed in the light of a negative chaperonotherapy, and the consequent development of inhibitors, as well as positive chaperonotherapy, in the event its excessive activity i…

Cpn60Excessive activityHsp60 inhibitoranimal structuresHeat shock proteinChemistryPyrazolopyrimidinefungiAvrainvillamidechemical and pharmacologic phenomenaComputational biologyMizoribineSettore CHIM/06 - Chimica OrganicaCarboranylphenoxyacetanilideHsp60complex mixturesGroELGroELHspD1Heat shock proteinHSP60AvrainvillamideEpolactaene
researchProduct

Lower Urinary Tract Symptoms: What's New in Medical Treatment?

2018

Abstract Context Pharmacological treatment is a cornerstone in the management of patients with lower urinary tract symptoms (LUTS). Objective To review emerging evidence in the medical treatment of LUTS. Evidence acquisition An Embase/Pubmed-based literature search was conducted in December 2017, screening for randomized controlled trials (RCTs), prospective and retrospective series, animal model studies, and reviews on medical treatment of LUTS. Evidence synthesis The main medical innovation in recent years in overactive bladder (OAB) has been the approval of the first β 3 -adrenoceptor agonists (mirabegron) and intradetrusor onabotulinum toxin A, while several other drugs such as antiepil…

Malemedicine.medical_specialtyReceptors VasopressinUrologyUrinary Bladder030232 urology & nephrologyUrologyProstatic HyperplasiaUrinary incontinenceAdrenergic beta-3 Receptor Agonistsurologic and male genital diseases03 medical and health sciences0302 clinical medicineLower Urinary Tract SymptomsLower urinary tract symptomsmedicineDesmopressin AcetateNocturiaHumansDeamino Arginine VasopressinProspective StudiesBotulinum Toxins Type ADesmopressinRandomized Controlled Trials as TopicRetrospective StudiesUrinary bladderbusiness.industryUrinary Bladder OveractiveAntidiuretic AgentsPhosphodiesterase 5 Inhibitorsmedicine.diseasefemale genital diseases and pregnancy complicationsThiazolesmedicine.anatomical_structureOveractive bladderClinical Trials Phase III as Topic030220 oncology & carcinogenesisModels AnimalAcetanilidesFemaleNocturiamedicine.symptomMirabegronbusinessmedicine.drugEuropean urology focus
researchProduct

Virtual Combinatorial Syntheses and Computational Screening of New Potential Anti-Herpes Compounds

1999

The activity of new anti-HSV-1 chemical structures, designed by virtual combinatorial chemical synthesis and selected by a computational screening, is determined by an in vitro assay. A virtual library of phenol esters and anilides was formed from two databases of building blocks: one with carbonyl fragments and the other containing both substituted phenoxy and phenylamino fragments. The library of virtually assembled compounds was computationally screened, and those compounds which were selected by our mathematical model as active ones were finally synthesized and tested. Our antiviral activity model is a "tandem" of four linear functions of topological graph-theoretical descriptors. A giv…

Models Molecularmedicine.drug_classStereochemistryChemical structureCarboxamideHerpesvirus 1 HumanViral Plaque AssayAntiviral AgentsChemical synthesisInhibitory Concentration 50Structure-Activity RelationshipPhenolsChlorocebus aethiopsDrug DiscoverymedicineIc50 valuesAnimalsStructure–activity relationshipAnilidesVero Cellschemistry.chemical_classificationBicyclic moleculeTandemChemistryEstersDicarboxylic acidMolecular MedicineJournal of Medicinal Chemistry
researchProduct

A randomized trial comparing tamoxifen therapy vs. tamoxifen prophylaxis in bicalutamide-induced gynecomastia.

2012

BACKGROUND: Tamoxifen (TAM) has been shown to be active against the bicalutamide-induced breast events (BEs) gynecomastia, and breast pain in patients with prostate cancer (PC). Optimal doses and schedules are not yet established. Debate still exists about whether prophylaxis with TAM is more effective than treatment of BEs when diagnosed. The results of a randomized study comparing TAM prophylaxis vs. TAM therapy are presented. METHODS: One hundred seventy-six patients with prostate cancer (PC) who were candidates for bicalutamide monotherapy were randomized to receive TAM 20 mg daily orally within 1 month from the onset of BEs (arm A) vs. TAM 10 mg daily starting simultaneously with bical…

OncologyMalemedicine.medical_specialtyBicalutamidemedicine.drug_classVisual analogue scaleUrologyBreast painBreast painAntineoplastic AgentsAntiandrogenStatistics Nonparametriclaw.inventionTosyl CompoundsProstate cancerstomatognathic systemRandomized controlled trialBicalutamidelawInternal medicineNitrilesmedicineHumansAnilidesskin and connective tissue diseasesAgedAged 80 and overProstate cancerbusiness.industryEstrogen AntagonistsProstatic NeoplasmsMiddle Agedmedicine.diseaseAntiandrogenTamoxifenTreatment OutcomeOncologyGynecomastiaChemotherapy AdjuvantGynecomastiamedicine.symptombusinesshormones hormone substitutes and hormone antagonistsTamoxifenmedicine.drugClinical genitourinary cancer
researchProduct

Studies in organic mass spectrometry. Part 23. Role of the aroyl group on the competitive fragmentation reactions of the molecular ion of aroylanilid…

1999

The 70 eV and mass-analysed ion kinetic energy (MIKE) spectra of some thiophenecarboxanilides and benzoylanilides (1–10) have been compared in order to investigate the role of the aroyl (or heteroaroyl) moiety on the abundance of the competitive fragmentation reactions occurring in their molecular ions (amide–bond cleavage and phenol radical ion formation). It has been shown that the electron ionisation induced decompositions with high (70 eV) and low (MIKE) internal energy excess are qualitatively similar, but remarkable quantitative differences have been observed that can be accounted for in terms of the different effectiveness in the transmission of electronic effects of substituents in …

substituent effectsChemistryrearrangement processesPolyatomic ionAnalytical chemistryaroylanilidesMass spectrometryPhotochemistryelectron ionisation; positive ions; ion chemistry; aroylanilides; substituent effects; rearrangement processesIonchemistry.chemical_compoundRadical ionFragmentation (mass spectrometry)positive ionsThiopheneElectronic effectMoietyion chemistryelectron ionisationSpectroscopy
researchProduct

Studies in organic mass spectrometry. Part 20: a hidden ortho effect in the electron ionisation mass spectra of some 2′-alkyl substituted 2-and 3-thi…

1996

The electron-ionisation-induced amide-bond cleavage of some 2′-methyl- and 2′-ethyl-substituted 2- and 3-thiophenecarboxanilides, which yields formally anilylium ions having relative intensities apparently in contrast with the Stevenson‐Audier rule, has been investigated by mass-analysed ion kinetic energy (MIKE) spectrometry and compared to that of the 3 ′- and 4′-isomers. It has been shown that, in the case of the 2 ′-methyl and 2′-ethyl derivatives, the amide-bond cleavage is anchimerically assisted through the hidden migration of a benzyl hydrogen to the nitrogen. Analysis of the MIKE and collision-induced decomposition (CID) MIKE spectra of model compounds indicates that this cryptic o…

IONSchemistry.chemical_classificationTHIOPHENE-2-CARBOXANILIDES; IONS; NMRHydrogenAnalytical chemistrychemistry.chemical_elementKinetic energyMass spectrometryNMRSpectral lineIonchemistryIonizationMass spectrumTHIOPHENE-2-CARBOXANILIDESPhysical chemistrySpectroscopyAlkylEuropean Journal of Mass Spectrometry
researchProduct